Spironolactone effect on circulating procollagen type I carboxy-terminal propeptide : Pooled analysis of three randomized trials
Copyright © 2023 Elsevier B.V. All rights reserved..
BACKGROUND: Spironolactone might improve the prognosis of patients with heart failure with preserved left ventricular ejection fraction (HFpEF), but the mechanisms by which it acts are uncertain. Serum concentrations of procollagen type I carboxy-terminal propeptide (PICP) reflect the synthesis of type I collagen and correlate well with histologically proven cardiac fibrosis.
AIMS: To investigate the effect of spironolactone on serum PICP concentration in patients with stage B and C HFpEF across three trials (HOMAGE, ALDO-DHF, and TOPCAT) for which measurements of serum PICP were available.
METHODS: Random-effects meta-analysis.
RESULTS: A total of 1038 patients with PICP measurements available both at baseline and 9-12 months were included in this analysis: 488 (47.0%) from HOMAGE, 386 (37.2%) from ALDO-DHF, and 164 (15.8%) from TOPCAT. The median (percentile25-75) serum PICP was 98 (76-128) ng/mL. Compared to placebo or usual care, administration of spironolactone for 9 to 12 months reduced serum PICP by -7.4 ng/mL, 95%CI -13.9 to -0.9, P-value =0.02. The effect was moderately heterogeneous (I2 = 64%) with the most pronounced effect seen in TOPCAT where PICP was reduced by -27.0 ng/mL, followed by HOMAGE where PICP was reduced by -8.1 ng/mL, and was least marked in ALDO-DHF where PICP changed by -2.9 ng/mL. The association between spironolactone and serum PICP was not mediated substantially by blood pressure.
CONCLUSIONS: Spironolactone reduced serum concentrations of PICP in patients with HFpEF with different severity and stages of disease. These findings are consistent with spironolactone having an anti-fibrotic effect.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:377 |
|---|---|
| Enthalten in: |
International journal of cardiology - 377(2023) vom: 15. Apr., Seite 86-88 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Ferreira, João Pedro [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
27O7W4T232 |
|---|
| Anmerkungen: |
Date Completed 15.03.2023 Date Revised 27.06.2023 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1016/j.ijcard.2023.01.088 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM35248862X |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM35248862X | ||
| 003 | DE-627 | ||
| 005 | 20231226053835.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.ijcard.2023.01.088 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1174.xml |
| 035 | |a (DE-627)NLM35248862X | ||
| 035 | |a (NLM)36738846 | ||
| 035 | |a (PII)S0167-5273(23)00171-7 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Ferreira, João Pedro |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Spironolactone effect on circulating procollagen type I carboxy-terminal propeptide |b Pooled analysis of three randomized trials |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 15.03.2023 | ||
| 500 | |a Date Revised 27.06.2023 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2023 Elsevier B.V. All rights reserved. | ||
| 520 | |a BACKGROUND: Spironolactone might improve the prognosis of patients with heart failure with preserved left ventricular ejection fraction (HFpEF), but the mechanisms by which it acts are uncertain. Serum concentrations of procollagen type I carboxy-terminal propeptide (PICP) reflect the synthesis of type I collagen and correlate well with histologically proven cardiac fibrosis | ||
| 520 | |a AIMS: To investigate the effect of spironolactone on serum PICP concentration in patients with stage B and C HFpEF across three trials (HOMAGE, ALDO-DHF, and TOPCAT) for which measurements of serum PICP were available | ||
| 520 | |a METHODS: Random-effects meta-analysis | ||
| 520 | |a RESULTS: A total of 1038 patients with PICP measurements available both at baseline and 9-12 months were included in this analysis: 488 (47.0%) from HOMAGE, 386 (37.2%) from ALDO-DHF, and 164 (15.8%) from TOPCAT. The median (percentile25-75) serum PICP was 98 (76-128) ng/mL. Compared to placebo or usual care, administration of spironolactone for 9 to 12 months reduced serum PICP by -7.4 ng/mL, 95%CI -13.9 to -0.9, P-value =0.02. The effect was moderately heterogeneous (I2 = 64%) with the most pronounced effect seen in TOPCAT where PICP was reduced by -27.0 ng/mL, followed by HOMAGE where PICP was reduced by -8.1 ng/mL, and was least marked in ALDO-DHF where PICP changed by -2.9 ng/mL. The association between spironolactone and serum PICP was not mediated substantially by blood pressure | ||
| 520 | |a CONCLUSIONS: Spironolactone reduced serum concentrations of PICP in patients with HFpEF with different severity and stages of disease. These findings are consistent with spironolactone having an anti-fibrotic effect | ||
| 650 | 4 | |a Meta-Analysis | |
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Anti-fibrotic therapy | |
| 650 | 4 | |a Fibrosis | |
| 650 | 4 | |a HFpEF | |
| 650 | 4 | |a Spironolactone | |
| 650 | 7 | |a Spironolactone |2 NLM | |
| 650 | 7 | |a 27O7W4T232 |2 NLM | |
| 650 | 7 | |a Procollagen Type I |2 NLM | |
| 650 | 7 | |a Procollagen |2 NLM | |
| 650 | 7 | |a Peptide Fragments |2 NLM | |
| 700 | 1 | |a Cleland, John G |e verfasserin |4 aut | |
| 700 | 1 | |a Girerd, Nicolas |e verfasserin |4 aut | |
| 700 | 1 | |a Rossignol, Patrick |e verfasserin |4 aut | |
| 700 | 1 | |a Pellicori, Pierpaolo |e verfasserin |4 aut | |
| 700 | 1 | |a Cosmi, Franco |e verfasserin |4 aut | |
| 700 | 1 | |a Mariottoni, Beatrice |e verfasserin |4 aut | |
| 700 | 1 | |a González, Arantxa |e verfasserin |4 aut | |
| 700 | 1 | |a Diez, Javier |e verfasserin |4 aut | |
| 700 | 1 | |a Solomon, Scott D |e verfasserin |4 aut | |
| 700 | 1 | |a Claggett, Brian |e verfasserin |4 aut | |
| 700 | 1 | |a Pfeffer, Marc A |e verfasserin |4 aut | |
| 700 | 1 | |a Pitt, Bertram |e verfasserin |4 aut | |
| 700 | 1 | |a Petutschnigg, Johannes |e verfasserin |4 aut | |
| 700 | 1 | |a Pieske, Burkert |e verfasserin |4 aut | |
| 700 | 1 | |a Edelmann, Frank |e verfasserin |4 aut | |
| 700 | 1 | |a Zannad, Faiez |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t International journal of cardiology |d 1984 |g 377(2023) vom: 15. Apr., Seite 86-88 |w (DE-627)NLM012621196 |x 1874-1754 |7 nnns |
| 773 | 1 | 8 | |g volume:377 |g year:2023 |g day:15 |g month:04 |g pages:86-88 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.ijcard.2023.01.088 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 377 |j 2023 |b 15 |c 04 |h 86-88 | ||